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Abstract: The EARS2 nuclear gene encodes mitochondrial glutamyl-tRNA synthetase, a member of the
class I family of aminoacyl-tRNA synthetases (aaRSs) that plays a crucial role in mitochondrial protein
biosynthesis by catalyzing the charging of glutamate to mitochondrial tRNA(Glu). Pathogenic EARS2
variants have been associated with a rare mitochondrial disorder known as leukoencephalopathy
with thalamus and brainstem involvement and high lactate (LTBL). The targeted sequencing of
150 nuclear genes encoding respiratory chain complex subunits and proteins implicated in the
oxidative phosphorylation (OXPHOS) function was performed. The oxygen consumption rate (OCR),
and the extracellular acidification rate (ECAR), were measured. The enzymatic activities of Complexes
I-V were analyzed spectrophotometrically. We describe a patient carrying two heterozygous EARS2
variants, c.376C>T (p.Gln126*) and c.670G>A (p.Gly224Ser), with infantile-onset disease and a
severe clinical presentation. We demonstrate a clear defect in mitochondrial function in the patient’s
fibroblasts, suggesting the molecular mechanism underlying the pathogenicity of these EARS2 variants.
Experimental validation using patient-derived fibroblasts allowed an accurate characterization of the
disease-causing variants, and by comparing our patient’s clinical presentation with that of previously
reported cases, new clinical and radiological features of LTBL were identified, expanding the clinical
spectrum of this disease.
Keywords: mitochondrial disorders; aminoacyl-tRNA synthetases; EARS2; LTBL
1. Introduction
Mitochondrial diseases are a group of clinically heterogeneous disorders caused by dysfunction
of the oxidative phosphorylation (OXPHOS) system and can arise due to defects in genes in the
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nuclear or mitochondrial DNA (nDNA and mtDNA, respectively) [1]. Human mtDNA contains
37 genes encoding 13 subunits of the OXPHOS complexes I, III, IV, and V and two ribosomal RNAs
(rRNA) and 22 transfer RNAs (tRNAs) crucial for their translation [2]. The remaining components of
mtDNA replication, transcription, and translation processes, including tRNA maturation, initiation
and elongation factors, ribosomal proteins, and aminoacyl-tRNA synthetases (mt-aaRSs), are encoded
by nDNA, synthesized in the cytosol, and imported into the mitochondria [3,4]. nDNA-encoded
mt-aaRS genes produce enzymes that play an important role in protein synthesis by charging tRNAs
with their cognate amino acid and ensuring the correct protein translation [5,6]. Pathogenic variants in
mt-aaRSs can directly affect the central nervous system (CNS), leading to characteristic brain lesion
patterns (e.g., leukodystrophies) that can be identified by magnetic resonance imaging (MRI) [4,7].
The nuclear gene EARS2 (MIM*612799) encodes glutamyl-tRNA synthetase, a member of the class
I family of mt-aaRSs. This 523-amino acid protein has an N-terminal mitochondrial targeting signal
that enables its importation from the cytoplasm into the mitochondria, where it catalyzes the acylation
of tRNAGln with glutamine [8,9]. Genetic defects in EARS2 may lead to combined OXPHOS deficiency
(MIM#614924), an autosomal recessive neurologic disorder caused by either compound heterozygous
or homozygous variants. Defects in EARS2 have been associated with a specific clinical syndrome
called leukoencephalopathy with thalamus and brainstem involvement and high lactate (LTBL) [10].
LTBL has a broad clinical spectrum, ranging from infantile-onset disease (usually after six months
of age) with relatively mild neurological symptoms, followed by spontaneous clinical, biochemical,
and radiological improvement, to a more severe phenotype with neonatal/early-infantile onset and
rapidly progressive CNS disease that stabilizes but does not improve [10–12]. Here, we demonstrate
the pathogenicity of EARS2 variants found in compound heterozygosity in a patient with a variation
of the classical LTBL phenotype, characterized by infantile-onset, with progression to a severe clinical
phenotype and cerebellar atrophy. We discuss the importance of carefully interpreting variant frequency
from population databases and of experimental validation using in-vitro analysis for the accurate
characterization of disease-causing variants.
2. Materials and Methods
2.1. Study Design
This study was carried out in collaboration with the University Clinical Hospital of Santiago de
Compostela (Santiago de Compostela, Spain) and Radboud University Medical Center (Nijmegen,
The Netherlands). The patient’s parents provided written informed consent to participation in the
study and publication of the results. The relevant clinical information from the medical record was
collected for the interpretation of the genetic results. For its execution, this project was submitted
for approval by the Autonomous Committee of Ethics of Clinical Research of Galicia (code 2015/410).
All experimental protocols were approved by the Radboud University Medical Center and were
performed in accordance with relevant guidelines and regulations.
2.2. Clinical Profile
Our female Spanish patient, the first child of healthy nonconsanguineous parents, was born at
42 weeks of gestation after an uneventful pregnancy. Birth weight, length, and head circumference
were all within the normal range. Beginning at 12 months of age, the patient presented daily episodes
of absence seizures with mild spasticity of the extremities, lateral pulling of the mouth to the right,
and sialorrhea. Electroencephalogram readings were initially normal, although results at 19 years
old showed irregular and slightly slowed brain activity for her age. Physical examination revealed
microcephaly. The patient required assistance to remain seated, which is her best motor performance
achieved. Hepatomegaly was absent. Laboratory analyses of blood, urine, and cerebrospinal fluid
(CSF) revealed elevated serum and CSF lactate but no alterations in creatine kinase, glucose, liver
function, or blood amino acid levels. Brain magnetic resonance imaging (MRI) revealed generalized
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leukodystrophy that predominantly affected the thalamus and complete agenesis of the corpus
callosum. Assessment of OXPHOS complex enzymatic activity in skeletal muscle at 1 years old revealed
a combined deficiency of complexes I and III. Histochemical studies showed normal cytochrome
C oxidase (COX) activity, with uniform caliber of the fibers, without structural alterations and no
ragged-red fibers. Patient’s mtDNA was sequenced, and the presence of pathogenic variants were
discarded. Absence seizures were well-managed at first with empirical phenobarbital treatment.
With the appearance of recurrent episodes, carbamazepine was added to the patient’s regimen and was
subsequently substituted with vigabatrin. The patient showed progressive intellectual and neurological
deterioration and, at 6 years of age, exhibited severe delayed psychomotor development, absence of
speech, and spastic tetraparesis. Growth remained poor, with head circumference in the 3rd percentile.
Serum lactate levels normalized, and brain MRIs at the ages of 10 and 15 years revealed complete
agenesis of the corpus callosum, severe atrophy of the cerebral white matter, and diffuse cerebellar
atrophy. By 17 years of age, complete seizure control had not been achieved, and levetiracetam
treatment was initiated in parallel with vigabatrin treatment. At follow-up at 19 years, the patient
was experiencing 2 seizures episodes per month and was slightly more alert and responsive, although
absence of speech and spastic tetraparesis persisted.
2.3. Targeted Next-Generation Sequencing
DNA was isolated from the patient’s lymphocytes and analyzed with targeted next-generation
sequencing (NGS) panels for mitochondrial diseases. In our unit, we have designed a multi-gene panel
consisting of 150 nuclear genes coding for respiratory chain complex subunits and proteins previously
implicated in OXPHOS function.
Genetic data were analyzed by NGS technology through a process consisting of enrichment
with an in-solution hybridization technology (Sure Select XT; Agilent Technologies, Santa Clara, CA,
USA), followed by subsequent sequencing on a Miseq platform (Illumina, San Diego, CA, USA).
A custom Sure Select probe library was designed to capture the exons and exon-intron boundaries
of the targeted genes [13]. Sequence capture, enrichment, and elution were performed in accordance
with the manufacturer’s instructions. Image analysis and processing of the sequence fluorescence
intensity (“base calling”) was performed with Real Time Analysis (RTA) software v.1.8.70 (Illumina),
and the FastQC v0.10.1 program was used for data quality control. Reads were aligned to the reference
genome GRCh37 using BWA v0.7.9a [14]. NGSrich v0.7.5 software [15] was used as a control prior
to variant detection and BEDTools 2.17.0 [16] and Picard 1.114 [17] for intermediate steps. VarScan
v.2.3.6 [18] and SAMtools v0.1.19 [19] were used for variant detection for indels and Single Nucleotide
Polymorphism (SNPs), respectively, and ANNOVAR for variant annotation [20].
To ensure reliable clinical interpretation of the detected variants, prioritization criteria were
applied to predict their pathogenicity in accordance with the ACMG assay mix containing 0.3-mM
acetyl-CoA guidelines [21].
2.4. Cell Culture
Patient fibroblasts from skin biopsy performed at 19 years old and a control fibroblast line routinely
used for research purposes were cultured in M199 medium (Gibco, Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% v/v fetal calf serum (FCS) and 1% v/v penicillin/streptomycin
(Gibco) at 37 ◦C and 5% CO2.
2.5. Mitochondrial Isolation
Pelleted fibroblasts from the patient and from the control cell line were resuspended in ice-cold
Tris-HCl (10 mM, pH 7.6). Cells were then disrupted in a Potter-Elvejhem homogenizer at 1800 rpm,
and sucrose (250 mM) was added to make the samples isotonic. The homogenized cell samples were
then centrifuged for 10 min at 600× g, and the mitochondria pellet was obtained after centrifugation of
the supernatant for 10 min at 14,000× g.
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2.6. Respirometry and Measurement of OXPHOS Activity
A Seahorse XFe96 Extracellular Flux analyzer (Seahorse Bioscience, Agilent) was used to measure
the oxygen consumption rate (OCR). On the day before the assay, control and patient fibroblasts were
seeded at 10,000 cells per well in cell culture medium (M199 supplemented with 10% FCS and 1%
pen/strep) and incubated overnight at 37 ◦C and 5% CO2. On the day of the assay, cell culture medium
was replaced with Agilent Seahorse XP Base Medium with 10-mM glucose (Sigma Aldrich, St. Louis,
MO, USA), 1-mM sodium pyruvate (Gibco), and 200-mM l-glutamine (Life Sciences Group, Barnet, UK)
and then incubated for 1 h at 37 ◦C without CO2. Baseline cellular OCR was measured 8 times, followed
by 4 measurement cycles after addition of the following inhibitors: 1-µM oligomycin A (Sigma), 2.0-µM
and 4.0-µM carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (Sigma), and 0.5-µM
rotenone and 0.5-µM antimycin A (Sigma). After OCR measurements, the cell medium was removed
and replaced with 0.33% Triton X-100, and 10-mM Tris-HCl (pH 7.6). Seahorse plates were stored
at −80 ◦C and thawed afterwards. Citrate synthase activity was measured spectrophotometrically,
at 37 ◦C, using a Tecan Spark spectrophotometer. The assay mix contained 0.3-mM acetyl-CoA, 0.1-mM
dithionitrobenzoic acid (DTNB), 0.025% Triton X-100, and 10-mM Tris-HCl, pH 8.1. Measurements
were based on the absorption at 412 nm of thionitrobenzoic acid (TNB), and citrate synthase activity
was calculated based on the rate of dithionitrobenzoic acid (DTNB) conversion in the presence of
oxaloacetate. OCR was measured before and after the addition of inhibitors and was normalized to the
activity of the citrate synthase (CS) [22] to avoid the effect of differences in the mitochondrial content
or cell number.
The enzymatic activities of complexes I–V were assayed spectrophotometrically using mitochondrial
extracts prepared as previously described in mitochondrial isolation. These measurements were
performed according to the current protocols in use in the Nijmegen Center for Mitochondrial
Disorders [23]. All assays were performed in duplicate using a Konelab 20XT auto-analyzer (Thermo
Fischer Scientific).
3. Results
3.1. Molecular Genetics and In-Silico Analysis of EARS2 Variants
NGS analysis enabled the identification of two compound heterozygous variants in EARS2
(NM_001083614.1) in our patient (Figure 1): variant c.670G>A (p.Gly224Ser) has been previously
described in a patient with mild LTBL [10], while c.376C>T (p.Gln126*) has not to date been included
in any human genetic variation database.
The identified EARS2 variants were analyzed in silico to determine the degree of evolutionary
conservation, predicted pathogenicity, functional consequences, and minor allele frequency (MAF)
within the population (Table S1, Supplementary Materials). According to GERP [24], PhyloP [25],
and phastCons [25], both variants are located in areas of the EARS2 protein that are highly conserved
through evolution. The pathogenicity was predicted using MutationTaster [26] (prediction and
disease-causing) and by calculating the FATHMM [27] and DANN [28] scores, which corresponded to
“damaging”. The missense variant c.670G>A is located in exon 4 and causes an amino acid change
from a nonpolar glycine to an uncharged polar serine at residue 224. Both SIFT [29] and Provean [30]
software predicted a damaging effect of this variant on the protein function. The nonsense variant
c.376C>T, located in exon 3, was predicted to be disease-causing and damaging by MutationTaster and
FATHMM, respectively.
Segregation studies were performed by Sanger sequencing to determine the inheritance pattern of
the identified variants (Figure 1). The missense variant was inherited from the patient’s mother and
the nonsense variant from the father.
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3.2. Mitochondrial Respiration and OXPHOS Activity
Measurement of the OCR and extracellular acidification rate (ECAR), normalized by the
mitochondrial content, revealed decreases in both the OCR and the OCR/ECAR ratio in the
patient’s fibroblasts, indicating a reduced electron flow through the respiratory chain (Figure 2A,B).
These findings reflect a general deficiency in the cumulative proficiency of the entire set of mitochondrial
respiratory chain complexes in the patient’s fibroblasts.
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phenylhydrazone (FCCP), and a mixture of rotenone and antimycin A), which a serially injected to
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(ECAR) ratios following the sequential injection of the inhibitors. (C) Measurements of the enzyme
activities for the different oxidative phosphorylation (OXPHOS) complexes in the patient’s fibroblasts
(reference range deemed in a healthy population). CS, citrate synthase.
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The spectrophotometric analysis of respiratory chain enzyme activity revealed a slight deficiency
in complex III in the patient’s fibroblasts and normal levels of activity of complexes I, II, IV, and V
(Figure 2C). Additionally, mitochondrial mass differences were detected between the patient and
control—160 U/L and 339 U/L, respectively—regarding the CS measurement.
4. Discussion
LTBL is a condition with a well-defined clinical phenotype, characterized by extensive symmetrical
deep white matter abnormalities and signal changes in the thalami and brainstem, along with lactic
acidosis [10,31]. Two distinct clinical courses are described: severe and moderate. The severe form is
characterized by early-onset, delayed psychomotor development, seizures, hypotonia, and persistently
elevated lactate levels, with progressive atrophy of the affected brain structures. The mild form usually
manifests clinically after six months of age with irritability and psychomotor regression, although
patients can show clinical and biochemical improvements. The occurrence and extent of recovery
most likely depends on the severity of brain damage caused by the first symptomatic episode; some
children with the most severe phenotype can die after the first clinical event [31–34]. Less common
findings reported in LTBL include anemia, tubulopathy, hepatopathy, absence of the thalami, and even
the absence of characteristic neuroimaging findings [10,35–37]. The clinical course of our patient does
not appear to correspond to either of the two clinical courses described: she has a severe clinical
presentation that initially manifested at 12 months of age, characterized by absence seizures with mild
spasticity of the extremities. In addition to the typical clinical features of LTBL, MRIs at 10 (Figure 3A)
and 15 (Figure 3B) years of age revealed diffuse atrophy of the cerebellum that was not present in
the early stages of the disease. Later-onset of cerebellar atrophy was also identified in a patient
reported by Steenweg et al. (Table S2, Supplementary Materials). In addition to the cerebellar atrophy
associated with LTBL (Table S2, Supplementary Materials), our patient exhibited progressive brain
lesions with no signs of improvement, which is commonly reported in cases diagnosed after four
months of age [10,36,38,39]. It has been difficult to establish a correlation between patients’ genotypic
and phenotypic characteristics, since the same variant may be associated with different clinical signs,
even among members of the same family [10,39].Genes 2020, 11, x FOR PEER REVIEW 7 of 11 
 
 
Figure 3. MRI images of our patient acquired at 10 (A) and 15 (B) years of age, showing complete 
agenesis of the corpus callosum (indicated with a red star) and cerebellar atrophy (indicated with 
white arrows). Note also the dilation of the fourth ventricle and enlargement of the interfolial spaces 
within a normal-sized posterior fossa. 
The evaluation of all LTBL cases with homozygous or compound heterozygous variants in 
EARS2 reported to date indicates that certain aspects of the established LTBL phenotype do not 
appear in all cases of this pathology. As shown in Table S2 of the Supplementary Materials, 
leukoencephalopathy was absent in patients 14 and 26, the thalamus and brainstem involvement 
was absent in patients 18 and 29, and lactic acidosis was absent in patient 18 (clinical conditions that 
do not correspond to the classical LTBL phenotype are shown in bold). 
The data presented here support the pathogenicity of the compound heterozygous EARS2 
variants detected in our patient. We provide the first description of the nonsense variant c.376C>T 
(p.Gln126*), inherited from the patient’s father. Our patient also carried the variant c.670G>A 
(p.Gly224Ser), which was previously identified in a patient (patient 7, Table S2) with mild LTBL by 
Steenweg et al. [10]. Although this variant has a high frequency in allele-population databases such 
as gnomAd and ExAC (0.00087 and 0.00119, respectively), especially in African populations, a 
software in-silico analysis predicted a high level of pathogenicity for this variant. The combination 
of severe changes, like nonsense with milder missense variants, is a common molecular mechanism 
in EARS2-associated diseases. 
Mitochondrial function characterization using the patient’s fibroblasts revealed a mitochondrial 
dysfunction due to abnormal mitochondrial respiration, as evidenced by a decrease in the 
OCR/ECAR ratio. The decrease in OCR and the increase in lactate production observed in our 
patient are likely the consequences of deficient respiration due to general impairment of the entire 
set of mitochondrial respiratory chain complexes. The analysis of respiratory chain enzymatic 
activity in muscle samples from our patient revealed deficiencies in complexes I and III. However, 
the same analysis of fibroblast samples only showed a mild decrease in complex III activity. Despite 
our patient’s severe clinical presentation and the clear deficit in fibroblast mitochondrial function, 
these discrepancies between muscle and fibroblast findings are not uncommon in nuclear-encoded 
gene-associated disorders [23]. Importantly, the various ARS2 gene defects are notoriously variable 
when it comes to issue-specific biochemical phenotypes [40]. 
Our findings highlight the complexity of OXPHOS enzymes. On the one hand, we have a 
system composed of multi-subunit enzymes encoded both by mtDNA and nDNA (except for 
complex II, which is only encoded by nDNA). Consequently, pathogenic variants in both genomes 
can lead to the highly heterogeneous clinical presentations characteristics of mitochondrial 
disorders. On the other hand, this tight relationship guarantees a close coevolution of the two 
genomes. Therefore, any inconsistency affecting either genome may have severe negative effects on 
the cellular fitness [41]. In fact, studies of Drosophila melanogaster have shown that interactions 
between nDNA-encoded mt-aaRSs and mitochondrial tRNAs may not only delay development and 
fecundity but, also, affect the activities of oxidative phosphorylation complexes I, III, and IV, 
Figure 3. MRI images of our patient acquired at 10 (A) and 15 (B) years of age, showing complete
agenesis of the corpus callosum (indicated with a red star) and cerebellar atrophy (indicated with white
arrows). Note also the dilation of the fourth ventricle and enlargement of the interfolial spaces within a
normal-sized posterior fossa.
evaluation of all LTBL cases with homozygous r compound heterozygous variants in EARS2
reported to date indic s that certain asp c s of the established LTBL p notype do not ap ar in all
cases of this pathology. As hown in Table S2 of the Supplementary Materials, l ukoencephalopathy
Genes 2020, 11, 1028 7 of 10
was absent in patients 14 and 26, the thalamus and brainstem involvement was absent in patients 18
and 29, and lactic acidosis was absent in patient 18 (clinical conditions that do not correspond to the
classical LTBL phenotype are shown in bold).
The data presented here support the pathogenicity of the compound heterozygous EARS2 variants
detected in our patient. We provide the first description of the nonsense variant c.376C>T (p.Gln126*),
inherited from the patient’s father. Our patient also carried the variant c.670G>A (p.Gly224Ser),
which was previously identified in a patient (patient 7, Table S2) with mild LTBL by Steenweg et al. [10].
Although this variant has a high frequency in allele-population databases such as gnomAd and ExAC
(0.00087 and 0.00119, respectively), especially in African populations, a software in-silico analysis
predicted a high level of pathogenicity for this variant. The combination of severe changes, like nonsense
with milder missense variants, is a common molecular mechanism in EARS2-associated diseases.
Mitochondrial function characterization using the patient’s fibroblasts revealed a mitochondrial
dysfunction due to abnormal mitochondrial respiration, as evidenced by a decrease in the OCR/ECAR
ratio. The decrease in OCR and the increase in lactate production observed in our patient are likely
the consequences of deficient respiration due to general impairment of the entire set of mitochondrial
respiratory chain complexes. The analysis of respiratory chain enzymatic activity in muscle samples
from our patient revealed deficiencies in complexes I and III. However, the same analysis of fibroblast
samples only showed a mild decrease in complex III activity. Despite our patient’s severe clinical
presentation and the clear deficit in fibroblast mitochondrial function, these discrepancies between
muscle and fibroblast findings are not uncommon in nuclear-encoded gene-associated disorders [23].
Importantly, the various ARS2 gene defects are notoriously variable when it comes to issue-specific
biochemical phenotypes [40].
Our findings highlight the complexity of OXPHOS enzymes. On the one hand, we have a system
composed of multi-subunit enzymes encoded both by mtDNA and nDNA (except for complex II,
which is only encoded by nDNA). Consequently, pathogenic variants in both genomes can lead to
the highly heterogeneous clinical presentations characteristics of mitochondrial disorders. On the
other hand, this tight relationship guarantees a close coevolution of the two genomes. Therefore,
any inconsistency affecting either genome may have severe negative effects on the cellular fitness [41].
In fact, studies of Drosophila melanogaster have shown that interactions between nDNA-encoded
mt-aaRSs and mitochondrial tRNAs may not only delay development and fecundity but, also, affect
the activities of oxidative phosphorylation complexes I, III, and IV, suggesting that these interactions
may be targets of compensatory molecular evolution [42]. Several features of mtDNA, including a high
mutation rate and uniparental inheritance, makes mtDNA more likely to accumulate mutations in the
population. These changes, in turn, could drive adaptations in nDNA, given the intimate interactions
between both genomes. In different populations, this coevolution is driven by different factors and in
different directions [41,43], leading to distinct consequences of nDNA-encoded variants, depending
on the mtDNA background. This could explain why variant c.670G>A (p.Gly224Ser), which was
detected in our patient and in the LTBL case described by Steenweg et al., is predicted as pathogenic
and associated with LTBL disease despite being classified as benign, owing to its high frequency in
African populations. This hypothesis underscores the need for caution when consulting population
frequency databases, particularly when studying variants in nuclear genes that interact directly with
mitochondrial genes.
Taken together, the results of the functional analyses and family studies presented here enabled the
correct identification of the pathogenicity of the variants identified in our patient, thereby expanding the
clinical spectrum of LTBL to include cerebellar atrophy. Establishing the pathogenicity has significant
implications for the diagnosis and management of these disorders. However, the relationship between
EARS2 variants and the phenotypic characteristics of LTBL remain poorly understood, and further
studies are needed to elucidate the molecular mechanisms underlying this disease.
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